Although skin rash has been hypothesised to be a potential prognostic factor for response to EGFR inhibitors, the lack of correlation between skin rash and clinical benefit over a wide range of gefitinib doses (150–1000 mg day−1) in clinical trials demonstrates that it should not be used to direct treatment with gefitinib. Here, EGFR is linked to exanthem.